#1 Clinical Trials Search in Europe

Tigecycline

Tigecycline is an antibiotic being studied in clinical trials for treating various bacterial infections. These trials aim to evaluate its safety, effectiveness, and optimal dosing in different patient populations and conditions. Researchers are investigating tigecycline’s potential for treating drug-resistant infections, complicated skin and intra-abdominal infections, and even certain types of leukemia. The trials provide valuable insights into how tigecycline performs in real-world clinical settings.

Table of Contents

What is Tigecycline?

Tigecycline is a broad-spectrum antibiotic medication used to treat various serious bacterial infections. It belongs to a class of antibiotics called glycylcyclines, which are derived from tetracycline antibiotics. Tigecycline is also known by the brand name Tygacil[1].

This antibiotic works by inhibiting the growth of bacteria that are resistant to many other antibiotics. It is particularly useful against multi-drug resistant pathogens, which are bacteria that have developed resistance to multiple types of antibiotics[2].

What Conditions Does Tigecycline Treat?

Tigecycline is approved to treat several types of serious infections, including:

  • Complicated intra-abdominal infections: These are infections that occur inside the abdomen and are typically more severe or difficult to treat[1].
  • Complicated skin and skin structure infections: These are serious infections of the skin and tissues beneath the skin[1].
  • Community-acquired bacterial pneumonia: This is a type of pneumonia (lung infection) that people get outside of hospitals or healthcare facilities[3].

Tigecycline is also being studied for its effectiveness against other types of infections, including:

  • Infections caused by multi-drug resistant Acinetobacter baumannii: This is a type of bacteria that can cause severe hospital-acquired infections and is often resistant to many antibiotics[2].
  • Rapidly growing mycobacterial infections: These are infections caused by a specific group of bacteria, including Mycobacterium abscessus, which can cause lung disease[4].
  • Catheter-related infections: These are infections associated with medical devices inserted into blood vessels[5].

How is Tigecycline Administered?

Tigecycline is given as an intravenous (IV) infusion, which means it’s delivered directly into a vein. The typical dosing regimen is:

  • An initial dose of 100 mg
  • Followed by 50 mg every 12 hours

The infusion is usually given over a period of 30 to 60 minutes[1][2]. The duration of treatment can vary depending on the type and severity of the infection, but it typically ranges from 7 to 14 days[1].

Effectiveness of Tigecycline

Clinical trials have shown that Tigecycline can be effective in treating various types of infections. The effectiveness is usually measured by:

  • Clinical response rate: This refers to the percentage of patients whose symptoms improve or resolve after treatment[1].
  • Microbiological eradication: This means the bacteria causing the infection are no longer detectable after treatment[3].

For example, in one study, the clinical response rate (patients who were cured or showed improvement) was reported to be around 60% for patients with multi-drug resistant infections[2].

Safety and Side Effects

Like all medications, Tigecycline can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Diarrhea
  • Headache
  • Skin rash

More serious side effects, though less common, can occur. These may include severe allergic reactions or effects on liver function. It’s important to report any unusual symptoms to your healthcare provider[3].

Use in Special Populations

Research is ongoing to understand how Tigecycline works in specific patient groups:

  • Patients with kidney problems: Studies are looking at how Tigecycline behaves in patients undergoing continuous renal replacement therapy (a type of dialysis)[6].
  • Patients with liver problems: The dosage may need to be adjusted in patients with severe liver dysfunction[7].
  • Obese patients: Research is being conducted to understand if dosing needs to be adjusted based on body weight[8].

Ongoing Research

Scientists continue to study Tigecycline to understand its full potential. Some areas of ongoing research include:

  • Its use in treating infections in patients with acute myeloid leukemia (a type of blood cancer)[9].
  • Its effectiveness against bacteria that are resistant to multiple other antibiotics[2].
  • How it performs in real-world hospital settings[10].

These studies help doctors understand how to use Tigecycline most effectively and safely in different patient groups and for various types of infections.

Aspect Details
Main Indications Studied Complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired bacterial pneumonia, multi-drug resistant bacterial infections
Administration Intravenous infusion, typically 50-100 mg every 12 hours, with some studies using higher doses up to 350 mg daily
Primary Outcomes Safety (adverse events), clinical effectiveness (cure or improvement), microbiological response (pathogen eradication)
Special Populations Patients with renal insufficiency, morbidly obese individuals, patients with liver cirrhosis, elderly patients
Potential Side Effects Nausea, vomiting, diarrhea; monitoring for more serious effects like liver problems and increased mortality risk in severe infections
Unique Applications Being studied for rapidly growing mycobacterial diseases and as a potential treatment for acute myeloid leukemia

FAQ

  • What types of infections is tigecycline being studied for? Tigecycline is being studied for various infections including complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired bacterial pneumonia, and infections caused by multi-drug resistant bacteria like Acinetobacter baumannii. It's also being investigated for treating rapidly growing mycobacterial diseases and acute myeloid leukemia.
  • How is tigecycline typically administered in these trials? In most trials, tigecycline is administered intravenously. The dosage and duration vary depending on the study, but common regimens include a loading dose of 100-200 mg followed by 50-100 mg every 12 hours. Some studies use higher doses, up to 350 mg daily, especially when investigating its use in conditions like leukemia.
  • What are the main outcomes being measured in tigecycline trials? The main outcomes being measured include safety (by monitoring adverse events), clinical effectiveness (often assessed as cure or improvement of infection symptoms), and microbiological response (eradication of pathogens). Some studies also look at pharmacokinetics, especially in special populations like obese patients or those with liver or kidney problems.
  • Are there any special populations being studied with tigecycline? Yes, several trials focus on special populations. These include patients with renal insufficiency undergoing continuous renal replacement therapy, morbidly obese individuals, patients with primary biliary cirrhosis, and elderly patients. These studies help determine if dosage adjustments are needed for these groups.
  • What are some potential side effects of tigecycline being monitored in these trials? While specific side effects vary between trials, researchers are generally monitoring for any adverse events. Common side effects of tigecycline can include nausea, vomiting, and diarrhea. More serious potential side effects that may be monitored include liver problems, pancreatitis, and increased risk of death in certain severe infections. The trials aim to better understand the safety profile of tigecycline in various patient populations and conditions.

Ongoing Clinical Trials on Tigecycline

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Clofazimine and Drug Combination for Treating Mycobacterium abscessus Lung Disease in Adult Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia Czechia France Greece Latvia Slovakia +1

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated. This helps determine the right dosage and frequency of administration.
  • Multi-Drug Resistant (MDR): Bacteria that have become resistant to multiple types of antibiotics, making infections caused by these bacteria more difficult to treat.
  • Continuous Renal Replacement Therapy (CRRT): A type of dialysis used for patients with acute kidney injury, providing continuous blood filtration and removal of waste products.
  • Test-of-Cure (TOC): An assessment done after completing antibiotic treatment to determine if the infection has been fully cured.
  • Adverse Drug Reaction (ADR): Any unintended and harmful reaction that occurs due to taking a medication at normal doses.
  • Microbiological Eradication: The complete removal or destruction of disease-causing microorganisms from a person's body or a specific site of infection.
  • Complicated Intra-Abdominal Infections (cIAI): Infections that extend beyond the hollow organ of origin into the peritoneal space, often requiring both surgical and antibiotic treatment.
  • Complicated Skin and Skin Structure Infections (cSSTI): Severe infections involving deeper soft tissue or requiring significant surgical intervention, often caused by a wider range of bacteria than uncomplicated skin infections.

References

  1. https://clinicaltrials.gov/study/NCT01789905
  2. https://clinicaltrials.gov/study/NCT01342731
  3. https://clinicaltrials.gov/study/NCT01072539
  4. https://clinicaltrials.gov/study/NCT00600600
  5. https://clinicaltrials.gov/study/NCT00419991
  6. https://clinicaltrials.gov/study/NCT02931526
  7. https://clinicaltrials.gov/study/NCT00406237
  8. https://clinicaltrials.gov/study/NCT01560143
  9. https://clinicaltrials.gov/study/NCT01332786
  10. https://clinicaltrials.gov/study/NCT00827541